Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8058019 | 0.88 | PTPN11 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21052511 | 0.88 | PTPN11 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29820043 | 0.87 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15603819 | 0.87 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8180164 | 0.85 | GABRA1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9081505 | 0.85 | PTPN11 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15603821 | 0.84 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7728547 | 0.84 | NQO2 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2335866 | 0.84 | ABL1 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7605479 | 0.83 | ALDH1A1 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818666-B2 | FOR EXAMPLE, METHYL 4-(5,5,8,8,-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2 -NAPHTHYLSULPHANYLETHYNYL)BENZOATE; USE IN HUMAN OR VETERINARY MEDICINE OR COSMETIC COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2004-11-16 | — | — | US | disclosed |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | GALDERMA RESEARCH & DEVELOPMENT | 2003-05-29 | — | — | US | disclosed |
| US-6441010-B2 | USEFUL AS COSMETIC FOR HAIR AND BODY HYGIENE, AND FOR TREATMENT OF DERMATOLOGICAL COMPLAINTS, WITH AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT OF RHEUMATIC OR RESPIRATORY TYPE, CARDIVASCULAR AND OPTHALMOGICAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-08-27 | — | — | US | disclosed |
| US-6368608-B1 | SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) (FR) | 2002-04-09 | — | — | US | disclosed |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | GALDERAMA RESEARCH & DEVELOPMENT. | 2001-12-27 | — | — | US | disclosed |
| US-6313162-B1 | FOR USE IN HUMAN OR VETERINARY MEDICINE SUCH AS DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHHALMOLOGICAL DISORDERS; AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) GALDERMA (FR) | 2001-11-06 | — | — | US | disclosed |
| US-6201019-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-03-13 | — | — | US | disclosed |
| US-6162445-A | Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| US-6150413-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, BONE AND OPHTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS; 4-(4-(BIPHENYL-2-YL)BUT-3-EN-1-YNYL)BENZOIC ACID, FOR EXAMPLE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-11-21 | — | — | US | disclosed |
| US-6046220-A | ADMINISTERING TO THE PATIENT A PROPYNYL OR DIENYL BIAROMATIC COMPOUND TO TREAT A SKIN DISORDER, INFLAMMATORY CONDITIONS, VISION DEFECTS, ALOPECIA, CARDIOVASCULAR DISORDER, CANCER OR PRECANCER AND INSULIN DEPENDANT DIABETES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-04-04 | — | — | US | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | TYR, KRT18, SCO2 | CA12 3949/4885CA1 4278/4885CA2 2232/4885 |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | TYR, AHR, CYP2C19 | CA12 4405/4885CA1 4881/4885CA2 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.